Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by NanoViricides, Inc.

NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application
From NanoViricides, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Tickers NNVC
NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis
From NanoViricides, Inc.
Via AccessWire
Exposures COVID-19
Tickers NNVC
NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program
From NanoViricides, Inc.
Via AccessWire
Exposures COVID-19
Tickers NNVC
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready
From NanoViricides, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Tickers NNVC
NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials
From NanoViricides, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Tickers NNVC
NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2
From NanoViricides, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Tickers NNVC
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
From NanoViricides, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Tickers NNVC
NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity
From NanoViricides, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Tickers NNVC
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND
From NanoViricides, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Tickers NNVC
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.